-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31

Benzinga·07/22/2026 18:45:45
Listen to the news
UBS analyst David Dai maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $23 to $31.